tradingkey.logo

Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease

ReutersMay 13, 2025 8:02 PM

- Absci Corp ABSI.O:

  • ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF ABS-101, A POTENTIAL BEST-IN-CLASS ANTI-TL1A ANTIBODY FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

  • ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2025

  • ABSCI CORP - ABS-101 SHOWS HIGH POTENCY AND QUARTERLY DOSING POTENTIAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI